Today, we are thrilled to share some exciting news: together with the Fisabio Foundation, we have filed a patent for several compounds targeting the CDK4 enzyme that “could inhibit” aggressive cancers such as glioblastoma.
The CDK4 enzyme accelerates the growth of cancer cells, and its inhibition could become a useful tool in treating various types of cancers where it is highly expressed.
The results were achieved through the collaboration of the research teams led by Miguel Saceda, Camino De Juan Romero, and José Antonio Encinar. The study was conducted both in silico—using computer simulations for drug design—and in vitro in cell lines. However, for these molecules to be approved as drugs, “several years of preclinical and clinical studies in different cell and animal models are still required.”
More information at this link.